Olaparib is a breast cancer treatment that could save lives. But it has been provisionally rejected for use on the NHS in England.

With your support, we could reverse that decision – but we need to act now.

Please sign our urgent petition calling for AstraZeneca, NICE and NHS England to work together to explore every possible solution, including AstraZeneca doing all it can to price the drug at a level that ultimately will ensure its availability.

Sign the petition

Take Action

Olaparib is a treatment option for people with high-risk HER2-negative primary breast cancer with an altered BRCA gene after surgery. It can reduce the risk of their cancer returning or progressing to become incurable secondary breast cancer. Crucially, it can reduce the risk of death by almost a third.

Please sign the petition today - it will only take you 30 seconds and you could help to make olaparib available on the NHS – and help save lives.

“It’s daunting to know that your breast cancer is less common and more aggressive than other types of breast cancer, with a higher risk of returning in the years immediately following treatment. I feel incredibly lucky to have been given the opportunity to benefit from olaparib. Given the significant reduction in the risk of breast cancer recurring that it provides It’s vital that other eligible women with primary breast cancer are able to benefit from olaparib too.”

A patient with BRCA positive, primary triple negative breast cancer, who has been receiving olaparib via the drug company’s early access programme.

Do you have experience of olaparib for primary breast cancer?

By sharing your experience, you could help us campaign to reverse this decision. 

Tell us your story

Frequently asked questions

Please sign the petition today

It will only take you 30 seconds and you could help to make olaparib available on the NHS – and help save lives.